trending Market Intelligence /marketintelligence/en/news-insights/trending/nik0xsehzcovcvvbziisyq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Mylan, Biocon biosimilar approved in EU, Australia

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Mylan, Biocon biosimilar approved in EU, Australia

The European Commission approved Semglee, a biosimilar version of Sanofi's blockbuster drug Lantus.

Mylan NV and India-based biotechnology company Biocon Ltd. co-developed the medicine, intended for diabetes patients. The biosimilar was also approved in Australia.

The companies are also seeking approval for Semglee in U.S. and Canada.

Sanofi's Lantus generated €4.62 billion in global sales in 2017, the most in its diabetes franchise, which had combined sales of €6.40 billion the same year.